Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's maker

Driven by a landmark cardiovascular outcomes trial that could spell blockbuster sales for its fish-oil derivative, Vascepa, Amarin has been a darling for pharma M&A speculators. Now, after Novartis' $9.7 billion agreement to pick up The Medicines Company, the rumor mill is back up and running.